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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of zinc to reduce the incidence, duration and severity of the common cold when used either as a daily supplement
to prevent colds or as therapy at the onset of cold symptoms or during a cold.
B A C K G R O U N D
Description of the condition
While familiar to most people, the ‘common cold’ is not a pre-
cisely defined disease (Eccles 2013). Typical cold symptoms in-
clude combinations of nasal symptoms, sore throat, cough and
fever. The common cold is a significant cause of absenteeism from
work and school.
The common cold is usually caused by one of a number of viruses.
The respiratory viruses include rhino, corona, adeno, parain-
fluenza, influenza and respiratory syncytial types, which together
have around 200 serotypes (Eccles 2009; Turner 2010). A num-
ber of non-respiratory viruses can also cause common cold-type
symptoms. However, in a third of people with cold symptoms,
the aetiology remains undefined even though extensive virological
tests may be carried out. Similar symptoms can also be caused by
mechanical irritation of the airways and from allergy or some bac-
terial infections. Hence, common cold symptoms do not always
imply viral aetiology.
In common cold trials, symptom-based definitions of the com-
mon cold are almost always used. However, there is no explicit
combination of symptoms and symptom duration that enables
conclusions to be drawn about the aetiology. There is thus no rig-
orous definition of the common cold and the symptoms can vary
substantially. It is the person’s subjective experience that prompts
a visit to a physician to seek treatment or to ask for sick leave
certification due to the common cold.
Most adults have one or two common cold episodes per year due
to naturally occurring common colds. Laboratory studies have
induced colds by inoculating high numbers of rhinovirus into the
nose, which causes nearly all study volunteers to develop common
cold symptoms within a few days.
Description of the intervention
Zinc is an essential nutrient for humans (Prasad 2013; Sandstead
2013). Zinc deficiency has been associated with increased suscep-
tibility to infections (Prasad 2013). Zinc deficiency is quite com-
mon in low-income countries, but mild deficiency has also been
observed in middle- and high-income countries (Prasad 2013). A
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meta-analysis of six studies conducted in Bangladesh, India, Peru
and South Africa concluded that zinc supplementation prevented
pneumonia and that low dietary zinc levels may have practical im-
portance in decreased resistance against infections (Lassi 2016).
To treat zinc deficiency, or marginal deficiency, zinc has been ad-
ministered as tablets and as a syrup (zinc supplements).
For the treatment of the common cold, zinc has also been admin-
istered as lozenges soon after the onset of symptoms (Eby 1984).
People with colds have been instructed to dissolve the lozenges
slowly in the mouth several times per day. Nose gels and sprays
have also been tested for treating the common cold.
In the USA, the recommended daily intake of zinc is 11 mg/day
for men and 8 mg/day for women (NRC 2001). However, zinc
has been administered in doses of 100 mg to 150 mg per day
to some people (not for the common cold) for several months
with few adverse effects (Bamford 2012; Pories 1967; Serjeant
1970). Copper deficiency has been reported as a consequence of
long-term zinc supplementation (Hoffman 1988; Prasad 1978),
although a six-week experiment in which 150 mg/day of zinc was
administered found no effect on plasma copper levels (Samman
1987). Due to the zinc and copper interaction, 150 mg/day of zinc
is currently one of the standard treatments for Wilson’s disease.
Most people with Wilson’s disease take 150 mg doses of zinc daily
for life (Ala 2007; Marcellini 2005). In the treatment of Wilson’s
disease, zinc has an excellent safety profile, although it caused
gastric irritation in 5% to 10% of people requiring therapy (Brewer
2005). The use of high-dose zinc for long periods in people with
Wilson’s disease indicates that zinc does not have long-term serious
adverse effects, except for copper deficiency, which is reversible.
How the intervention might work
Zinc participates in the function of about 300 enzymes and has a
range of effects on the immune system (Prasad 2008; Prasad 2013).
For example, zinc has been reported to inhibit the replication
of rhinovirus and respiratory syncytial virus (Geist 1987; Korant
1976; Suara 2004) and to enhance the effects of interferon (Berg
2001). However, the mechanism by which zinc supplements have
an effect on pneumonia is not clearly understood (Lassi 2016).
The major hypothesis in the use of zinc lozenges to treat the com-
mon cold is that the effect is due to local effects of free zinc ions in
the oro-pharyngeal region (Eby 2010). However, the molecular-
level mechanism of the effect of zinc lozenges for common cold
treatment is not known. Although zinc might influence the local
immune system, non-immune mechanisms have also been pro-
posed to explain the effect of zinc lozenges on the common cold
(Novick 1996; Novick 1997). The formulation of zinc lozenges
appears to be critical (Eby 2010). Zinc binds effectively to citrate,
and zinc lozenges containing citrate or citric acid do not release
free zinc ions (Eby 1988; Eby 2010; Godfrey 1988; Martin 1988).
Zinc acetate and zinc gluconate have been used as salts in zinc
lozenges. Zinc acetate has been proposed as the better salt in zinc
lozenges because acetate binds to zinc ions very weakly, whereas
gluconate binds the zinc ions more effectively. Given the stronger
binding, zinc gluconate has been proposed as a less suitable con-
stituent for zinc lozenges (Eby 2010). However, it is uncertain if
variation in zinc ion binding leads to significant differences at the
clinical level in the treatment of the common cold.
Why it is important to do this review
The common cold causes significant global morbidity, but iden-
tifying simple and effective preventive or therapeutic agents has
been elusive. Even modest benefits for defined populations could
be an important advantage from a public health perspective. In a
survey of people with the common cold in the USA, about half
had received antibiotics (Barnett 2014), although antibiotics are
not usually of any benefit, since the common cold is caused mostly
by viruses. Indiscriminate use of antibiotics can be harmful at both
individual and population levels. Alternative treatment options
such as zinc are therefore worth investigating.
Previous systematic reviews of zinc and the common cold have
various shortcomings. Caruso 2007 used vote counting, that is
counting the number of positive and negative studies, and had a
number of other inadequacies (Hemilä 2013). Eby 2010 found
dose-dependent effects of zinc lozenges on the common cold, but
did not take into account variation in study size or calculate confi-
dence intervals for the effect. Science 2012 combined zinc lozenge
trials with zinc tablet and syrup trials, although zinc tablets and
syrups were not intended to be dissolved in the oro-pharyngeal
region, leading to the problem of combining ‘apples with oranges’
(Hemilä 2012). Since zinc tablets and syrups appear to have a dif-
ferent mechanism of effect to zinc lozenges, we will analyse them
separately. A Cochrane Review on zinc and the common cold had
a number of problems and was withdrawn (Hemilä 2015; Singh
2015). Given the issues with previous reviews, a thorough review
is now warranted.
O B J E C T I V E S
To assess the effects of zinc to reduce the incidence, duration and
severity of the common cold when used either as a daily supple-
ment to prevent colds or as therapy at the onset of cold symptoms
or during a cold.
M E T H O D S
Criteria for considering studies for this review
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Types of studies
We will include parallel-group randomised controlled trials
(RCTs) including the first period of cross-over studies and cluster-
RCTs if there are 10 or more clusters. We will include studies re-
ported as full text, those published as abstracts only, and unpub-
lished data. We will restrict our review to placebo-controlled tri-
als. The common cold is a subjective experience, and there can be
great variation among people in how they classify their symptoms
and when they consider themselves to have recovered. However,
as such subjective variation applies similarly to both intervention
and placebo group participants, it should not lead to any bias.
Subjectivity in the assessment of common cold symptoms can in-
crease inaccuracy, which can lead to false-negative findings, but is
unlikely to lead to false-positive findings in studies with adequate
blinding.
Types of participants
We will include adults and children of either gender and any age.
We will define children as people aged up to 18 years and adults
as those aged 18 years and over. We will define older adults as
those aged 65 years and over. We will not exclude studies with
participants who have comorbidities.
We will include prevention trials that involved participants who
did not have common cold symptoms before the intervention
started.
We will include treatment trials that involved participants who
had cold symptoms before the intervention started.
We will include studies in which participants had either natural
common colds or induced common colds. We will analyse preven-
tion trials and treatment trials data separately. We will also analyse
natural common colds and induced common colds separately.
Types of interventions
We will include trials investigating oral zinc (tablets and syrups
but not lozenges) versus placebo, zinc lozenges versus placebo, and
nasal zinc administration versus placebo.
There will be no limitation on zinc dose administered by any route
or duration of therapy.
We will not exclude studies with co-interventions.
Types of outcome measures
Because common cold is not a precisely defined disease, we will
describe the definitions for the common cold applied in the in-
cluded studies in ’Characteristics of included studies’ tables in the
review.
Primary outcomes
1. Incidence of colds during regular supplementation will be
assessed as the proportion of participants experiencing one or
more colds during the study period.
2. Duration of the common cold (i.e. time from cold onset to
recovery).
3. Rate of recovery (i.e. how many participants recover on a
given day) from the common cold.
4. Adverse effects (e.g. taste disturbances and stomach
irritation).
Secondary outcomes
1. Severity of the common cold. Symptom severity is often
measured on a scale, one scale for each symptom. The severity
scores for each symptom are summed to provide a total severity
score for a specific day. We will compare the average severity in
the zinc groups with the average severity in the placebo groups.
2. Complications of the common cold (e.g. otitis, sinusitis,
and exacerbation of asthma).
We will analyse measures of effect separately for prophylactic oral
zinc (excluding lozenge) trials, prophylactic zinc lozenge trials, oral
zinc (excluding lozenge) therapeutic trials, zinc lozenge therapeutic
trials, and nasal zinc administration trials.
Search methods for identification of studies
Electronic searches
We will search the following databases from inception to present:
• Cochrane Central Register of Controlled Trials
(CENTRAL), which contains the Cochrane Acute Respiratory
Infection Group Specialised Register;
• PubMed; and
• Embase (Elsevier).
We will use the search strategy described in Appendix 1 to search
PubMed. We will modify this search appropriately for other
databases and clinical trials registers.
We will also search ClinicalTrials.gov (www.clinicaltrials.gov) and
the World Health Organization International Clinical Trials Reg-
istry Platform (WHO ICTRP) (apps.who.int/trialsearch/).
Searching other resources
We will check reference lists of all primary studies and review
articles for additional references. We will contact experts in the
field to identify additional unpublished material.
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Data collection and analysis
Selection of studies
Two review authors (HH, EC) will independently screen titles and
abstracts identified as a result of the searches to select potentially
eligible trials). We will retrieve the full-text study reports/publica-
tions, and two review authors (HH, EC) will independently screen
the full texts and identify studies for inclusion, and identify and
record reasons for exclusion of the ineligible studies. Any disagree-
ments will be resolved through discussion. We will identify and
exclude duplicates and collate multiple reports of the same study
so that each study rather than each report is the unit of interest
in the review. We will record the selection process in sufficient
detail to complete a PRISMA flow diagram and ’Characteristics
of excluded studies’ table (Moher 2009). We will include studies
reported as full text, those published as abstract only, and unpub-
lished data. We will not impose any language restrictions.
Data extraction and management
We will use a data collection form for study characteristics and
outcome data that has been piloted on at least one study in the
review. One review author (HH) will extract the following study
characteristics from the included studies.
1. Methods: study design, total duration of study, details of
any ’run in’ period, number of study centres and location, study
setting, withdrawals, and date of study.
2. Participants: N, mean age, age range, gender, diagnostic
criteria, inclusion criteria, and exclusion criteria.
3. Interventions: intervention, comparison, concomitant
medications, and excluded medications.
4. Outcomes: primary and secondary outcomes specified and
collected, and time points reported.
5. Notes: funding for trial, and notable conflicts of interest of
trial authors.
Two review authors (HH, EC) will independently extract outcome
data from the included studies. We will note in the ’Characteristics
of included studies’ table if outcome data are not reported in a
usable format. We will resolve disagreements by consensus. One
review author (HH) will transfer data into the Review Manager 5
file (Review Manager 2014). Both review authors (HH, EC) will
double check that data are entered correctly by comparing the data
presented in the systematic review with those in the study reports,
and they will check study characteristics against the trial reports
and data collection forms for accuracy.
Assessment of risk of bias in included studies
Two review authors (HH, EC) will independently assess risk of
bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Any disagreements will be resolved by discussion. We will assess
the risk of bias according to the following domains.
1. Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel.
4. Blinding of outcome assessment.
5. Incomplete outcome data.
6. Selective outcome reporting.
7. Other bias.
We will grade each potential source of bias as high, low, or un-
clear and provide a quote from the study report together with a
justification for our judgement in the ’Risk of bias’ table. We will
summarise the ’Risk of bias’ judgements across different studies for
each of the domains listed. We will consider blinding separately
for different key outcomes, where necessary. Where information
on risk of bias relates to unpublished data or correspondence with
a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol
and report any deviations from it in the ’Differences between pro-
tocol and review’ section of the systematic review.
Measures of treatment effect
We will enter the outcome data for each study into the data tables
in Review Manager 5 to calculate the treatment effects (Review
Manager 2014).
We will calculate the risk ratio (RR) for dichotomous outcomes.
We will calculate the effect of zinc on common cold duration in
days, and we will calculate the pooled mean difference (MD) es-
timate. Because duration is a time-related outcome, we will also
conduct survival analysis in accordance with guidance in Section
9.2.6 of the Cochrane Handbook for Systematic Reviews of Interven-
tions (Higgins 2011). Survival analysis enables visual inspection
and formal analysis of possible time-dependent variations in treat-
ment effects. Survival analysis is not confounded by censored data
or outlier participants who had particularly long colds. In con-
trast, outliers may decrease the statistical power of a t-test when
examining cold duration, because these data inflate the standard
deviation estimates.
Unit of analysis issues
If there are several zinc arms for a single placebo group, we will
divide the placebo group for the zinc arms if we show several zinc
arms in the same analysis table. If we find cross-over trials, we will
include data for the first observation period. Because the common
cold is contagious and different groups of people have different
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levels of incidence, we will include cluster-randomised trials only
if there are 10 or more clusters. In such cases, we will conduct
the analysis at the same level as the allocation, using a summary
measurement from each cluster.
Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and to obtain missing numerical outcome data
where possible (e.g. when a study is identified as abstract only).
Where this is not possible, and the missing data are thought to in-
troduce serious bias, we will explore the impact of excluding such
studies in the overall assessment of results by a sensitivity analysis.
If numerical outcome data such as standard deviations or corre-
lation coefficients are missing and cannot be obtained from the
authors, we will calculate them from other available statistics such
as P values according to the methods described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Assessment of heterogeneity
We will use the I² statistic to estimate heterogeneity among the
trials in each analysis. We will also use the Chi² test to calculate the
P value for the heterogeneity. We will consider an I² value of 50%
or more to represent a substantial level of heterogeneity, though
heterogeneity is not a dichotomous issue (Higgins 2003).
If we identify substantial heterogeneity, we will report this and
explore possible causes in prespecified subgroup analyses.
Assessment of reporting biases
We will construct funnel plots, but will interpret them cautiously,
since there are a number of problems with the use of funnel plots
in the assessment of publication bias (Ioannidis 2007; Lau 2006;
Sterne 2011; Terrin 2005). We will also narratively consider the
possibility of publication bias in the Discussion section.
Data synthesis
We will pool data from studies judged to be clinically homoge-
neous using Review Manager 5 software (Review Manager 2014).
If more than one study provides usable data for any single com-
parison, we will perform fixed-effect meta-analysis.
GRADE and ’Summary of findings’ table
We will create one ’Summary of findings’ table with different sec-
tions for prophylactic oral zinc (not lozenge) trials, prophylactic
zinc lozenge trials, oral zinc (not lozenge) therapeutic trials, zinc
lozenge therapeutic trials, and nasal zinc administration trials. We
will use the following outcomes: incidence and duration of the
common cold and adverse effects in zinc prophylactic trials; du-
ration of the common cold and adverse effects in oral zinc thera-
peutic trials; duration of the common cold and adverse effects in
nasal zinc therapeutic trials.
We will use the five GRADE considerations (study limitations,
consistency of effect, imprecision, indirectness, and publication
bias) to assess the quality of a body of evidence as it relates to the
studies that contribute data to the meta-analyses for the prespeci-
fied outcomes (Atkins 2004). We will use methods and recommen-
dations described in Section 8.5 and Chapter 12 of the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011),
using GRADEpro GDT software (GRADEpro GDT 2015). We
will justify all decisions to down- or upgrade the quality of studies
using footnotes, and we will make comments to aid the reader’s
understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to conduct subgroup analysis to investigate the preventive
effects of zinc for people in low-income countries compared with
those in middle- and high-income countries. We will use the World
Bank 2017 classification to determine countries’ income status.
In the analysis of treatment effects, we intend to perform subgroup
analyses for children, adults, and older adults where possible.
We will also explore the effects of zinc lozenges for:
1. dose of elemental zinc per day: < 75 mg versus ≥ 75 mg;
and
2. zinc acetate lozenges versus zinc gluconate lozenges in zinc
lozenge trials with doses ≥ 75 mg/day.
We will use the Chi² test to test for subgroup interactions in Review
Manager 5 (Review Manager 2014).
If there are several studies that are clinically so similar that they can
be considered to measure the same effect, we may consider car-
rying out meta-regression to simultaneously analyse several sub-
group variables. However, meta-regression is not a valid approach
if there are fewer than 10 trials, as described in Section 9.6.4 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
Sensitivity analysis
We plan to perform sensitivity analyses excluding trials:
• with methodological shortcomings leading to inadequate
randomisation or blinding; and
• those with missing data that required imputation.
A C K N O W L E D G E M E N T S
The methods section of this protocol is based on a standard tem-
plate developed by the Cochrane Airways Group and adapted
by the Cochrane Acute Respiratory Infections Group. We wish
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of this protocol: Ann Fonfa, Janet Wale, Craig Mellis, Martin
Meremikwu, Teresa Neeman, and Paul Little.
R E F E R E N C E S
Additional references
Ala 2007
Ala A, Walker AP, Ashkan K, Dooley JS, Schilsky ML.
Wilson’s disease. Lancet 2007;369(9559):397–408.
Atkins 2004
Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y,
Flottorp S, et al. GRADE Working Group. Grading quality
of evidence and strength of recommendations. BMJ 2004;
328(7454):1490.
Bamford 2012
Bamford JT, Gessert CE, Haller IV, Kruger K, Johnson BP.
Randomized, double-blind trial of 220 mg zinc sulfate twice
daily in the treatment of rosacea. International Journal of
Dermatology 2012;51(4):459–62.
Barnett 2014
Barnett ML, Linder JA. Antibiotic prescribing for
adults with acute bronchitis in the United States, 1996-
2010. JAMA 2014;311(19):2020–1. [DOI: 10.1001/
jama.2013.286141; PUBMED: 24846041
Berg 2001
Berg K, Bolt G, Andersen H, Owen TC. Zinc potentiates
the antiviral action of human IFN-alpha tenfold. Journal of
Interferon and Cytokine Research 2001;21(7):471–4.
Brewer 2005
Brewer GJ, Askari FK. Wilson’s disease: clinical
management and therapy. Journal of Hepatology 2005;42
(Suppl 1):S13–21.
Caruso 2007
Caruso TJ, Prober CG, Gwaltney JM Jr. Treatment of
naturally acquired common colds with zinc: a structured
review. Clinical Infectious Diseases 2007;45(5):569–74.
Eby 1984
Eby GA, Davis DR, Halcomb WW. Reduction in duration
of common cold by zinc gluconate lozenges in a double-
blind study. Antimicrobial Agents in Chemotherapy 1984;25
(1):20–4.
Eby 1988
Eby GA. Stability constants of zinc complexes affect
common cold treatment results. Antimicrobial Agents in
Chemotherapy 1988;32(4):606–7.
Eby 2010
Eby GA 3rd. Zinc lozenges as cure for the common cold -
a review and hypothesis. Medical Hypotheses 2010;74(3):
482–92.
Eccles 2009
Eccles R, Weber R (editors). Common Cold. Basel:
Birkhauser, 2009. [DOI: 10.1007/978-3-7643-9912-2
Eccles 2013
Eccles R. Is the common cold a clinical entity or a cultural
concept?. Rhinology 2013;51(1):3–8. [DOI: 10.4193/
Rhino12.123; PUBMED: 23441305
Geist 1987
Geist FC, Bateman JA, Hayden FG. In vitro activity of zinc
salts against human rhinoviruses. Antimicrobial Agents in
Chemotherapy 1987;31(4):622–4.
Godfrey 1988
Godfrey JC. Zinc for the common cold. Antimicrobial
Agents in Chemotherapy 1988;32(4):605–6.
GRADEpro GDT 2015 [Computer program]
McMaster University (developed by Evidence Prime).
GRADEpro GDT. Version accessed prior to 12 July 2017.
Hamilton (ON): McMaster University (developed by
Evidence Prime), 2015.
Hemilä 2012
Hemilä H. Zinc acetate lozenges may shorten common
cold duration by up to 40%. hdl.handle.net/10138/40083
(accessed prior to 1 March 2017).
Hemilä 2013
Hemilä H. Zinc and the common cold: problems in the
review by Caruso et al (2007). hdl.handle.net/10138/
40817 (accessed prior to 1 March 2017).
Hemilä 2015
Hemilä H. Concerns about unattributed copying of text
and data, and about numerous other problems in the
Cochrane Review “Zinc for the common cold” by Singh M,
Das RR (2013). hdl.handle.net/10138/153180 (accessed
prior to 1 March 2017).
Higgins 2003
Higgins JP, Thompson SG, Deeks JJ, Altman DG.




Higgins JP, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
Hoffman 1988
Hoffman HN, Phyliky RL, Fleming CR. Zinc-induced
copper deficiency. Gastroenterology 1988;94(2):508–12.
Ioannidis 2007
Ioannidis JP, Trikalinos TA. The appropriateness of
asymmetry tests for publication bias in meta-analyses: a
large survey. CMAJ : Canadian Medical Association Journal
6Zinc for preventing and treating the common cold (Protocol)




Korant BD, Butterworth BE. Inhibition by zinc of
rhinovirus protein cleavage: interaction of zinc with capsid
polypeptides. Journal of Virology 1976;18(1):298–306.
Lassi 2016
Lassi ZS, Moin A, Bhutta ZA. Zinc supplementation for
the prevention of pneumonia in children aged 2 months to
59 months. Cochrane Database of Systematic Reviews 2016,
Issue 12. [DOI: 10.1002/14651858.CD005978.pub3
Lau 2006
Lau J, Ioannidis JP, Terrin N, Schmid CH, Olkin I. The
case of the misleading funnel plot. BMJ 2006;333(7568):
597–600. [DOI: 10.1136/bmj.333.7568.597; PUBMED:
16974018
Marcellini 2005
Marcellini M, Di Ciommo V, Callea F, Devito R,
Comparcola D, Sartorelli MR, et al. Treatment of Wilson’s
disease with zinc from the time of diagnosis in pediatric
patients: a single-hospital, 10-year follow-up study. Journal
of Laboratory and Clinical Medicine 2005;145(3):139–43.
Martin 1988
Martin RB. pH as a variable in free zinc ion concentration
from zinc containing lozenges. Antimicrobial Agents in
Chemotherapy 1988;32(4):608–9.
Moher 2009
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA
Group. Preferred reporting items for systematic reviews and
meta-analyses: The PRISMA statement. BMJ 2009;339:
2535.
Novick 1996
Novick SG, Godfrey JC, Godfrey NJ, Wilder HR. How
does zinc modify the common cold? Clinical observations
and implications regarding mechanisms of action. Medical
Hypotheses 1996;46(3):295–302.
Novick 1997
Novick SG, Godfrey JC, Pollack RL, Wilder HR. Zinc-
induced suppression of inflammation in the respiratory
tract, caused by infection with human rhinovirus and other
irritants. Medical Hypotheses 1997;49(4):347–57.
NRC 2001
National Research Council. Zinc. Dietary Reference Intakes
for Vitamin A, Vitamin K, Arsenic, Boron, Chromium,
Copper, Iodine, Iron, Manganese, Molybdenum, Nickel,
Silicon, Vanadium, and Zinc. Washington, DC: National
Academies Press, 2001:442–501.
Pories 1967
Pories WJ, Henzel JH, Rob CG, Strain WH. Acceleration of
wound healing in man with zinc sulphate given by mouth.
Lancet 1967;1(7482):121–4.
Prasad 1978
Prasad AS, Brewer GJ, Schoomaker EB, Rabbani P.
Hypocupremia induced by zinc therapy in adults. JAMA
1978;240(20):2166–8.
Prasad 2008
Prasad AS. Zinc in human health: effect of zinc on immune
cells. Molecular Medicine 2008;14(5-6):353–7.
Prasad 2013
Prasad AS. Discovery of human zinc deficiency: its impact
on human health and disease. Advances in Nutrition 2013;4
(2):176–90.
Review Manager 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Samman 1987
Samman S, Roberts DC. The effect of zinc supplements on
plasma zinc and copper levels and the reported symptoms in
healthy volunteers. Medical Journal of Australia 1987;146
(5):246–9.
Sandstead 2013
Sandstead HH. Human zinc deficiency: discovery to initial
translation. Advances in Nutrition 2013;4(1):76–81.
Science 2012
Science M, Johnstone J, Roth DE, Guyatt G, Loeb M.
Zinc for the treatment of the common cold: a systematic
review and meta-analysis of randomized controlled trials.
CMAJ : Canadian Medical Association Journal 2012;184
(10):E551–61.
Serjeant 1970
Serjeant GR, Galloway RE, Gueri MC. Oral zinc sulphate
in sickle-cell ulcers. Lancet 1970;2(7679):891–2.
Sterne 2011
Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau
J, et al. Recommendations for examining and interpreting
funnel plot asymmetry in meta-analyses of randomised
controlled trials. BMJ 2011;343:d4002. [DOI: 10.1136/
bmj.d4002; PUBMED: 21784880
Suara 2004
Suara RO, Crowe JE. Effect of zinc salts on respiratory
syncytial virus replication. Antimicrobial Agents in
Chemotherapy 2004;48(3):783–90.
Terrin 2005
Terrin N, Schmid CH, Lau J. In an empirical evaluation
of the funnel plot, researchers could not visually identify




Turner RB. The common cold. In: Mandell GL, Bennett
JE, Dolin R editor(s). Principles and Practice of Infectious
Diseases. 7th Edition. Vol. 1, Philadelphia: Churchill
Livingstone, 2010:809–14.
World Bank 2017
World Bank. World Bank Country and Lending Groups.
datahelpdesk.worldbank.org/knowledgebase/articles/
906519 (accessed prior to 12 July 2017).
7Zinc for preventing and treating the common cold (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
References to other published versions of this review
Marshall 2000
Marshall I. Zinc for the common cold. Cochrane Database
of Systematic Reviews 2000, Issue 2. [DOI: 10.1002/
14651858.CD001364
Marshall 2006
Marshall I. Zinc for the common cold. Cochrane Database
of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/
14651858.CD001364.pub2
Singh 2011
Singh M, Das RR. Zinc for the common cold. Cochrane
Database of Systematic Reviews 2011, Issue 2. [DOI:
10.1002/14651858.CD001364.pub3
Singh 2013
Singh M, Das RR. Zinc for the common cold. Cochrane
Database of Systematic Reviews 2013, Issue 6. [DOI:
10.1002/14651858.CD001364.pub4
Singh 2015
Singh M, Das RR. Zinc for the common cold. Cochrane
Database of Systematic Reviews 2015, Issue 4. [DOI:
10.1002/14651858.CD001364.pub5
∗ Indicates the major publication for the study
A P P E N D I C E S
Appendix 1. MEDLINE search strategy
(“Zinc Acetate”[Mesh] OR “Zinc Compounds”[Mesh] OR “Zinc”[Mesh] OR Zinc[tiab] OR Galzin[tiab] OR Zincteral[tiab)
AND
(“Common Cold”[Mesh] OR “Rhinovirus”[Mesh] OR Cold[tiab] OR Colds[tiab] OR Rhinovirus[tiab] OR Rhinoviruses[tiab] OR
Coryza[tiab] OR Catarrh[tiab] OR Catarrhs[tiab] OR “Respiratory infection”[tiab] OR “Respiratory infections”[tiab])
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